NCT05430906View on ClinicalTrials.gov

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 25, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

January 31, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

AK104 - Chemotherapy

AK104 10mg/kg then \[paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)\] and \[carboplatin (AUC5 or 6) or cisplatin (75mg/m²)\] of each 21-day cycle

Trial Locations (1)

410000

RECRUITING

Hunan Cancer hospital, Changsha

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER